Xtant Medical Holdings, INC

Xtant Medical Holdings, Inc. announced its first quarter 2026 financial results, reporting a net loss of $3.1 million and raising its full-year revenue guidance to $101-$105 million.

Xtant Medical Holdings, Inc. has entered into an exclusive U.S. distribution agreement with Dilon Technologies, Inc. for the HEMOBLAST Bellows surgical hemostatic agent.

Xtant Medical reported a transformational 2025, achieving full-year profitability and positive operating cash flow, driven by revenue growth and strategic divestitures.

Xtant Medical Holdings, Inc. announced the full repayment of a $8.2 million promissory note and additional payments from Companion Spine, totaling $10.7 million, and used a portion to prepay its term loan.

Xtant Medical Holdings, Inc. announced an extension of the maturity date for an $8.2 million promissory note and a $1.742 million purchase price adjustment payment related to recent divestitures.

Xtant Medical Holdings, Inc. completed the sale of its Coflex and CoFix products and its international Paradigm Spine business for an initial $19.2 million, reducing debt and sharpening strategic focus.

Xtant Medical Holdings reported a 37% decrease in total revenue for the first quarter of 2026 compared to the prior year, primarily due to asset divestitures and a reduction in license revenue.

Xtant Medical Holdings, Inc. reported a significant turnaround in net income and gross profit for the nine months ended September 30, 2025, driven by licensing revenue and orthobiologics sales, while progressing with a strategic asset divestiture.

Xtant Medical Holdings, Inc. reported a significant financial turnaround in Q2 2025, achieving net income and substantial revenue growth, while announcing strategic divestitures of its Coflex/CoFix and international hardware businesses.

Xtant Medical Holdings, Inc. announces an 18% increase in revenue for the first quarter of 2025, driven by growth in orthobiologics sales and new licensing revenue.

Xtant Medical Holdings, Inc. announced its third-quarter 2024 results, showing a 12% increase in revenue compared to the same period last year, driven by recent acquisitions.

Xtant Medical Holdings saw a significant 48% increase in revenue in the second quarter of 2024 compared to the same period last year, driven by recent acquisitions, but continues to operate at a loss.

Xtant Medical Holdings, Inc. achieved net income in 2025 driven by license revenue and orthobiologics sales, despite divesting Coflex/CoFix assets and international hardware business, which will impact 2026 revenues.

Xtant Medical Holdings, Inc. reports a revenue increase for fiscal year 2024 driven by acquisitions and licensing agreements, but also reports a net loss due to increased operating expenses and interest expense.

Xtant Medical Holdings extends the termination deadline for its asset purchase agreement with Surgalign and files its annual 10-K report detailing financial results and strategic initiatives.

Xtant Medical Holdings, Inc. CFO Scott C Neils disposed of 8,084 common shares to cover tax withholding obligations related to restricted stock unit vesting.

Xtant Medical Holdings director John K. Bakewell filed an amended Form 4 to correct his beneficial ownership, disclosing a new deferred stock unit award.

Xtant Medical Holdings Director Stavros G. Vizirgianakis acquired 553,797 shares of common stock through a deferred stock unit award.

Xtant Medical Holdings Director Jonn R. Beeson acquired 158,228 deferred stock units, increasing his beneficial ownership.

Xtant Medical Holdings, Inc. Director John K. Bakewell was granted 158,228 deferred stock units, vesting in November 2026.

Xtant Medical Holdings, Inc. director Abhinav Jain received a deferred stock unit award of 158,228 shares, vesting in November 2026.

Xtant Medical Holdings, Inc. has filed definitive additional proxy soliciting materials with the SEC.

Xtant Medical Holdings, Inc. announces its 2025 Annual Meeting agenda, including director elections, auditor ratification, and a significant increase in its equity incentive plan share reserve.

Xtant Medical Holdings will hold its annual meeting of stockholders on July 23, 2024, to vote on director elections, auditor ratification, and executive compensation.

Xtant Medical Holdings has filed a registration statement for the resale of up to 73,114,592 shares of its common stock by selling stockholders following a privately negotiated stock purchase agreement.

Xtant Medical Holdings, Inc. announced the appointment of Abhinav Jain, an analyst from significant shareholder Nantahala Capital Management, to its Board of Directors.

Nantahala Capital Management and its affiliated funds have acquired a substantial block of Xtant Medical Holdings, Inc. common stock, increasing their beneficial ownership to 49.1% of the company.

OrbiMed Advisors LLC and OrbiMed ROF II LLC have filed an exit Schedule 13D/A, reporting the sale of their entire beneficial ownership in Xtant Medical Holdings, Inc., reducing their stake to 0%.

Laurence W. Lytton and the Lytton-Kambara Foundation have disclosed beneficial ownership of 5.5% and 5.0% respectively, in Xtant Medical Holdings, Inc. common stock.

Laurence W. Lytton has filed a Schedule 13G, reporting beneficial ownership of 6.8% of Xtant Medical Holdings, Inc.'s common stock.